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Introduction
Migraine is a chronic condition characterised by epi-
sodic attacks of disabling headaches that are generally
pulsatile in nature and often associated with gastro-
intestinal disturbances, photophobia, phonophobia
and neurological disruptions in cognition and mood
(1). In some migraineurs, focal neurological disrup-
tions, called auras, occur prior to the onset of head-
ache. In the United States, approximately 18% of
women suffer from at least one migraine headache
per year compared with 6% of men (2). The preva-
lence of migraine peaks during the most productive
adult years (25–55 years of age) creates a signiﬁcant
social and economic burden (3,4). One study found
that the healthcare costs for a family with a migrai-
neur were 70% higher than for the matched families
without a migraine sufferer (5).
For patients who seek migraine treatment through
their healthcare providers, a member of the triptan
drug class may be prescribed for the acute treatment
of migraine attacks (6). The efﬁcacy of triptans for
severe migraines was established in clinical trials ﬁrst
with sumatriptan (7–10). The evaluation of triptans
for the treatment of moderate-to-severe migraines
was required by regulatory authorities, and the pri-
mary end-point in these early studies was the reduc-
tion in moderate or severe pain to mild or no pain
(11). In this treatment paradigm, subjects who expe-
rienced mild headaches as a prelude to moderate-to-
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Aims: To evaluate treatment satisfaction, efﬁcacy and functional ability of the
rapid release formulation of sumatriptan 100 mg tablets (sumatriptan RT 100 mg)
in an early intervention paradigm in patients who were dissatisﬁed with low-dose
sumatriptan and not completely satisﬁed with their current migraine regimen.
Methods: Experienced migraineurs who reported a mild migraine pain phase, dis-
satisfaction with the previous sumatriptan treatment and some dissatisfaction with
their current treatment regimen had no experience with sumatriptan at the
100 mg dose were enrolled in an open-label, single group study. Subjects were
instructed to treat four migraine attacks within 30 min of the onset of mild pain.
Treatment satisfaction was measured with the Patient Perception of Migraine
Questionnaire Revised version (PPMQ-R) questionnaire. Results: More than half of
the subjects were either very satisﬁed or satisﬁed with the efﬁcacy of early inter-
vention sumatriptan RT 100 mg after each attack and at the follow-up study visit.
The mean total PPMQ-R score was 75.2 out of 100. Between 63% and 73% of
subjects were pain-free within 4 h of dosing. Between 79% and 90% of subjects
reported an ability to function normally within 4 h of taking the study medication.
Conclusion: Subjects who were previously unsatisﬁed with lower doses of suma-
triptan and less than very satisﬁed with their current treatment regimen were more
likely to be satisﬁed or very satisﬁed with sumatriptan RT 100 mg in an early
intervention paradigm. Results were consistent across four migraine attacks and at
a follow-up visit. The treatment satisfaction results corresponded with positive
results on efﬁcacy measures and a functional status measure.
What’s known
Sumatriptan RT 100 mg tablets effectively treat
migraine headaches in an early treatment
paradigm.
What’s new
Patients who were previously unsatisﬁed with lower
doses of conventionally formulated and other
formulations of sumatriptan therapy are more likely
to report that they are satisﬁed with sumatriptan
RT 100 mg treatment when used in an early
intervention paradigm.
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until their headache pain was moderate or severe
(12). The results of the recently published clinical
evidence and pathophysiological studies suggest that
the drugs in the triptan class provide greater efﬁcacy
when administered during the mild headache phase
of migraine, an early intervention paradigm, rather
than delaying treatment and sustaining the disability
of a moderate-to-severe headache (13–20). Modelling
studies suggest that early intervention is also more
cost-effective than waiting for moderate or severe
pain to develop because early intervention more
effectively controls pain and reduces the need for res-
cue medication (21,22). Controlled clinical trials with
sumatriptan have shown that early intervention
improves pain-free efﬁcacy and reduces migraine
pain and symptom duration (15,17,19). The Interna-
tional Headache Society now recommends that efﬁ-
cacy studies for migraine treatments include studies
of medications in an early intervention paradigm
(11).
In an early intervention paradigm, the optimal
dose and rapid delivery of the medication may
improve effectiveness and treatment satisfaction by
preventing progression in the migraine cycle. Multi-
ple studies of conventional sumatriptan administered
in an early intervention paradigm have demonstrated
that the 100 mg dose is more efﬁcacious than lower
doses at providing pain-free response in a clinical
trial setting (15,18,19,23). Recently, oral sumatriptan
was reformulated with RT technology to disperse
rapidly and disintegrate in the stomach to improve
absorption. Gastric scintigraphic evaluation of the
reformulated and conventional tablets conﬁrms that
the reformulated tablet disperses, disintegrates and is
absorbed faster in migraineurs (24). Randomised
controlled trials conﬁrm that the reformulated tablets
are efﬁcacious (25,26).
The objectives of this study were to evaluate treat-
ment satisfaction, efﬁcacy and functional ability asso-
ciated with the rapid release formulation of
sumatriptan 100 mg tablets (sumatriptan RT
100 mg) in an early intervention paradigm (within
30 min of onset of pain and while still mild) among
patients who were dissatisﬁed with the previous low-
dose sumatriptan treatment and who were not com-
pletely satisﬁed with their current migraine treatment
regimen. Patient reported outcomes such as treat-
ment satisfaction are increasingly considered end-
points that encompass the overall treatment experi-
ence (27). The Federal Drug Administration (FDA)
is encouraging the medical research community to
measure patient reported outcomes and has released
a draft guidance document with the goal of describ-
ing how the FDA will evaluate effectiveness data col-
lected using patient reported outcomes measures in
clinical trials (28). By providing an overview of the
patient’s perspective of treatment successes or short-
comings, treatment satisfaction results provide clini-
cally meaningful information to help inform
treatment decisions.
Methods
Study population
The study population included female and male mi-
graineurs aged 18–65 years with a diagnosis of
migraine, with or without aura (2004 IHS Criteria
ICHD-II diagnosis 1.2.1 and 1.1) (1), at least a
1-year history of migraine headaches and an average
of 2–6 migraine attacks per month in the 2 months
prior to screening. Subjects were required to report
that they typically experience a mild pain phase pre-
ceding a moderate to severe pain phase of migraine,
that they could distinguish mild-onset migraine
headaches from other types of headache, that they
had been dissatisﬁed with previous sumatriptan
treatment in any formulation (e.g. tablet, subcutane-
ous injection or nasal spray) at a dose < 100 mg and
that they were less than very satisﬁed with their cur-
rent acute treatment regimen. At the time of enrol-
ment, subject satisfaction with their current
treatment regimen was measured by a single-item
question with a 7-point response scale. Subjects who
rated their satisfaction with current treatment as
‘very satisﬁed’ were excluded from the study.
Subjects who were using sumatriptan as part of
their current migraine treatment regimen were
excluded because discontinuation of the previous
sumatriptan therapy was viewed as a sign of dissatis-
faction with treatment. To measure patient satisfac-
tion with a new therapy at a higher dose, patients
who had used the 100 mg dose of sumatriptan prior
to the study start were also excluded.
Study design
Treatment satisfaction, treatment efﬁcacy and func-
tional status were measured in a multi-centre, open-
label, single group, prospective study. Subjects were
required to attend two study visits: one at study
entry (screening) and one at study exit (follow up).
Follow-up visits were conducted within 2 weeks of
the last treated attack or at 8 weeks after the screen-
ing visit.
Procedures
At the screening visit, subjects were provided with
four tablets of sumatriptan RT 100 mg for the initial
treatment of mild migraine headaches and ﬁve tab-
lets of sumatriptan RT 100 mg for rescue use during
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if needed. Other rescue medications (excluding
ergotamine, ergot-type medications and other trip-
tans) were permitted when taken at least 2 h after
the initial dose of study medication and documented
in the patient diary. Subjects were not required to
meet a minimum level of pain severity as a prerequi-
site for taking rescue medications. Ergotamine or
ergot-type medications (e.g. dihydroergotamine and
methysergide) and other triptans were not allowed
during the 24 h before or after administration of the
study medication.
Subjects were instructed to treat four consecutive
migraine attacks within 30 min of the onset of mild
pain and to refrain from using study medication to
treat attacks with moderate or severe pain at onset.
Subjects were allowed to continue migraine prophy-
lactic medications provided the medication had been
included in their previous regimen for at least
1 month prior to screening.
Measures
Subjects were instructed to complete a patient diary
entry for each attack treated with study medication.
The patient diary required subjects to record the date
and time migraine pain started, the date and time of
the ﬁrst dose of study medication, the pain severity
level, the presence or absence of symptoms and the
level of functional impairment. The treatment satis-
faction questionnaire was included in the patient
diary. The diary also captured the date, time and the
type of rescue medication; the pain severity level at
the time of rescue; and all medications, excluding
study medications and daily medications, taken 24 h
before and after the study medication doses.
In the patient diary, subjects recorded their pain
severity level, associated symptoms and functional
ability at the time of dosing and 30 min, 1, 2, 4 and
24 h after dosing. Pain severity level was measured
on a 4-point scale (‘none’, ‘mild’, ‘moderate’ or
‘severe’). Subjects reported the presence or absence
of nausea, vomiting, photophobia and phonophobia.
Subjects recorded their ability to function on a
5-point scale (‘not impaired’, ‘mildly impaired’,
‘moderately impaired’, ‘severely impaired’ or
‘required bed rest’).
Treatment satisfaction with sumatriptan RT
100 mg was assessed using the Patient Perception of
Migraine Questionnaire Revised version (PPMQ-R).
Subjects were instructed to complete the PPMQ-R at
24 h after taking the ﬁrst dose of study medication
for each treated attack. Subjects also completed the
PPMQ-R at the follow-up visit.
The PPMQ-R is a validated patient satisfaction
instrument containing 32 items that contribute to
four scales: Tolerability (10 items), Efﬁcacy (11
items), Functionality (four items) and Ease of Use
(two items). The items contributing to the Efﬁcacy,
Functionality and Ease of Use scales were scored on
a scale ranging from 1 (very dissatisﬁed) to 7 (very
satisﬁed). The items contributing to the Tolerability
scale were scored on a scale ranging from 1 (extre-
mely bothersome) to 5 (not at all bothersome). A
total score was calculated based on the average of
scores for Efﬁcacy, Functionality and Ease of Use
(29,30).
In addition to the items contributing to the Efﬁ-
cacy, Functionality, Ease-of-Use and Tolerability
scales, the PPMQ-R contains three global satisfaction
items – one each measuring overall satisfaction, satis-
faction with medication effectiveness and satisfaction
with side effects. The global satisfaction items were
scored on a scale ranging from 1 (very dissatisﬁed)
to 7 (very satisﬁed) (29,30).
Two PPMQ-R items designed to measure satisfac-
tion with drug cost were excluded from the study
questionnaire because study medication was provided
as part of the clinical trial. The PPMQ-R has demon-
strated reliability and validity in measuring patient
satisfaction with acute migraine treatment (29,30).
At the follow-up visit, subjects returned unused
study drug and completed diaries. Subjects also com-
pleted follow-up questions and the PPMQ-R. For the
PPMQ-R, subjects were instructed to consider their
experience with the study drug across all attacks trea-
ted during the study.
Analysis
All subjects who took at least one dose of sumatrip-
tan RT 100 mg were included in the safety popula-
tion. The intention to treat (ITT) population
included subjects who treated at least one attack
according to the treatment instructions (i.e.
migraines were treated within 30 min of the onset of
the migraine headache pain and during a mild pain
phase). Data from attacks in which subjects did not
comply with the protocol with respect to treatment
instructions were not included in the analyses. As a
result, summaries on a per-attack basis will have dif-
ferent denominators based on the number of obser-
vations from subjects who treated the speciﬁc attack
according to the treatment instructions.
For the PPMQ-R, mean scores were calculated
from the item scores for each of the four scales (Efﬁ-
cacy, Functionality, Ease of Use and Tolerability).
Each scale score ranges from 0 to 100, with higher
scores indicating greater satisfaction or better tolera-
bility. A total score, a composite of the scale scores
for Efﬁcacy, Functionality and Ease of Use, was also
computed. Previous research suggests that a 5-point
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Use scale scores and the Total score is clinically
meaningful (26,27). Global satisfaction items (effec-
tiveness, side effects and overall) were summarised as
percentage of subjects by response option.
Descriptive statistics were calculated for efﬁcacy
and functional ability end-points. The percent of
patients who were pain-free at each time point was
calculated. The percent of patients reporting the
presence of nausea, photophobia and phonophobia
was calculated at dosing and each time point. The
percent of patients reporting normal functioning at
dosing and 30 min, 1, 2, 4 and 24 h after dosing was
calculated.
Results
Subject characteristics at baseline and
demographic data
A total of 140 subjects from six sites in the United
States were enrolled and 134 (96%) returned their
patient diaries. The safety population consisted of
120 subjects who were randomised and treated. The
ITT population included 105 subjects who treated at
least one migraine according to the study instruc-
tions. In the safety population, 9% withdrew prema-
turely. Three were lost to follow up, one because of
an adverse event, one withdrew consent, one for an
unspeciﬁed protocol violation and four for unknown
or other reasons.
A majority of subjects in the ITT population were
women (88%) and Caucasian (88%). The average
age of study subjects was 41 years (Table 1). The
mean number of migraines per month at baseline
was 3.9, and more than 99% of subjects reported
that their migraines typically lasted more than 4 h.
Of the subjects in the ITT population, 43% reported
that they typically have migraines lasting more than
24 h. Subjects reported a median of 24 years since
onset of migraine disease, and 80% reported experi-
encing migraines for more than 10 years. Severe
migraines were reported by 75% of the subjects.
More than half of all subjects (68%) were diagnosed
with migraine without aura compared with 8% who
were diagnosed with migraine with aura, and 23%
who were diagnosed with migraine with and without
aura.
Of the subjects who had discontinued previous su-
matriptan therapy at a dose lower than 100 mg,
more patients had taken sumatriptan in the 50 mg
tablet form (65%) than any other form (Table 1).
The most commonly reported reason for discontinu-
ation was lack of efﬁcacy.
In the 3 months prior to study enrolment, 93% of
subjects reported using any pharmacological treat-
ment. Pharmacological treatments included other
triptans (55%), over-the-counter analgesics (46%),
narcotics (22%) and prescription NSAIDS (19%). As
per the protocol, no subject reported that he⁄she was
very satisﬁed with the current treatment regimen.
Three percent (3 of 101) were satisﬁed with their
current migraine mediations and 37% were some-
what satisﬁed with their current migraine medica-
tions. Five percent of subjects were neither satisﬁed
nor dissatisﬁed with their current treatment. A total
of 35% of subjects were somewhat dissatisﬁed, 13%
were dissatisﬁed and 8% were very dissatisﬁed with
their current migraine treatment regimen.
Satisfaction results
Global satisfaction items from the PPMQ-R
Based on the results from the PPMQ-R overall satis-
faction question measured at the follow-up visit,
26% of subjects who were not very satisﬁed with
their previous treatment regimen were very satisﬁed
with sumatriptan RT 100 mg in an early intervention
paradigm (Figure 1). More than 50% of subjects
were either very satisﬁed or satisﬁed with the study
drug for attacks 2 through 4 and at follow up.
Table 1 Demographics and migraine type for the ITT
population
ITT population
(n = 105)*
Mean age (SD) 41.2 years
(11.2 years)
Gender, n⁄N (%)
Female 90⁄102 (88%)
Male 12⁄102 (12%)
Race, n⁄N (%)
Caucasian 90⁄102 (88%)
Asian 4⁄102 (4%)
African American 1⁄102 (<1%)
Hispanic 3⁄102 (3%)
Other 4⁄102 (4%)
Previous form of sumatriptan therapy, n⁄N (%)
Tablet, 25 mg 39⁄105 (37%)
Tablet, 50 mg 68⁄105 (65%)
Subcutaneous injection 39⁄105 (37%)
Nasal spray 40⁄105 (38%)
Migraine type, n⁄N (%)
Without aura 71⁄105 (68%)
With aura 8⁄105 (8%)
With and without aura 24⁄105 (23%)
Unknown 2⁄105 (2%)
*Demographic information was missing for three subjects in
the ITT population. Migraines type was deﬁned by the ICHD-2
classiﬁcation from the IHS (1). ITT, intention to treat.
1892 Treatment satisfaction and efﬁcacy of the rapid release formulation of sumatriptan
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, December 2008, 62, 12, 1889–1899Thirty-eight of 77 subjects (49%) were satisﬁed or
very satisﬁed after treating the ﬁrst attack.
More than half of all subjects were either very sat-
isﬁed or satisﬁed with the efﬁcacy of early interven-
tion sumatriptan RT 100 mg after each attack and at
the follow-up study visit (Figure 2). With the excep-
tion of the ﬁrst attack, more than half of all subjects
were very satisﬁed or satisﬁed with side effects asso-
ciated with the study drug (Figure 3). Less than 15%
of subjects were dissatisﬁed or very dissatisﬁed with
the side effect proﬁle of sumatriptan RT 100 mg fol-
lowing all attacks and at the follow-up visit.
PPMQ-R Scale scores and total score
The mean PPMQ-R scores are presented in Figure 4
for each of the fours attacks and at the follow-up
visit. For the Efﬁcacy scale, the mean score was > 60
for all four attacks and at the follow-up visit. Mean
scores for Functionality ranged from 61.8 for attack
1 to 70.2 for attack 4. At the follow-up visit, the
mean score for Functionality was 67.9. The mean
Ease of Use scores ranged from 88.8 for attack 3 to
91.9 for attack 4. The mean score for Ease of Use
was 90.1 at the follow-up visit. For the Tolerability
scale of the PPMQ-R, a higher score indicates better
tolerability and the mean score at ﬁnal visit was 88.6.
The total score is calculated by the average of Efﬁ-
cacy, Functionality and Ease of Use scale scores. For
attack 1, the mean total score was 71.4. For attacks
2, 3 and 4, the mean scores were 72.7, 73.2 and 77.9
respectively. The mean score at follow up was 75.2.
Efﬁcacy and functional impairment results
Between 53% (attack 1) and 61% (attack 4) of sub-
jects reported being pain-free within 2 h of taking
the ﬁrst dose of study medication (Figure 5). Within
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between 63% (attack 2) and 73% (attack 4) of sub-
jects were pain-free. Between 35% (attack 1) and
45% (attack 3) of subjects had taken either a second
dose of study drug or another approved rescue medi-
cation between 2 and 24 h after the initial dose
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prophylaxis ranged from 23% (attack 4) to 28%
(attack 1) (Table 2).
When compared with symptoms at the time of
dosing, reports of nausea, photophobia and phono-
phobia were lower at 2, 4 and 24 h postdose for all
Table 2 Number and percentage of patient taking rescue medications and migraine prophylaxis by attack
Attack 1
(n = 78)
Attack 2
(n = 73)
Attack 3
(n = 67)
Attack 4
(n = 62)
Rescued: n (%) 27 (35%) 26 (36%) 30 (45%) 22 (35%)
Mean (SD) hours to rescue 8.8 (7.5) 8.6 (8.2) 9.0 (7.4) 10.0 (8.3)
Pain severity at rescue: n (%)
Mild 10 (37%) 14 (54%) 16 (53%) 13 (59%)
Moderate 15 (56%) 7 (27%) 11 (37%) 5 (23%)
Severe 2 (7%) 5 (19%) 3 (10%) 4 (22%)
Migraine prophylaxis 22 (28%) 20 (27%) 17 (25%) 14 (23%)
Rescue medications include those the subject said were for migraine pain or a second dose of study drug taken 0–24 h after initial
dose of study drug.
Table 3 Summary of the incidence of symptoms associated with migraine by attack
Attack 1 Attack 2 Attack 3 Attack 4
Symptoms n⁄N (%)
Nausea
Present at dosing 21⁄76 (28%) 25⁄73 (34%) 18⁄67 (27%) 23⁄62 (37%)
Present 2 h after dosing 19⁄78 (24%) 15⁄73 (21%) 15⁄67 (22%) 14⁄62 (23%)
Present 4 h after dosing 11⁄78 (14%) 9⁄73 (12%) 6⁄67 (9%) 5⁄62 (8%)
Present 24 h after dosing 4⁄78 (5%) 3⁄73 (4%) 5⁄67 (7%) 1⁄62 (2%)
Photophobia n⁄N (%)
Present at dosing 46⁄78 (59%) 47⁄73 (64%) 47⁄67 (70%) 45⁄62 (73%)
Present 2 h after dosing 24⁄78 (31%) 23⁄73 (32%) 23⁄67 (34%) 20⁄62 (32%)
Present 4 h after dosing 15⁄78 (19%) 15⁄73 (21%) 15⁄67 (22%) 9⁄62 (15%)
Present 24 h after dosing 10⁄78 (13%) 8⁄73 (11%) 10⁄67 (15%) 3⁄62 (5%)
Phonophobia n⁄N (%)
Present at dosing 44⁄77 (57%) 43⁄73 (59%) 40⁄67 (60%) 41⁄62 (66%)
Present 2 h after dosing 20⁄77 (26%) 23⁄73 (32%) 22⁄67 (33%) 20⁄62 (32%)
Present 4 h after dosing 14⁄77 (18%) 17⁄73 (23%) 11⁄67 (16%) 10⁄62 (16%)
Present 24 h after dosing 12⁄77 (16%) 7⁄73 (10%) 9⁄67 (13%) 4⁄62 (6%)
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Figure 6 Percentage of subjects who reported normal functional ability at dosing and at speciﬁed intervals postdose for
each attack
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three reports of vomiting were reported.
Between 79% (attacks 1 and 2) and 90% (attack
4) of subjects reported an ability to function nor-
mally within 24 h of taking the study medication
(Figure 6). Following the ﬁrst attack, 24 subjects
(31%) reported that their pain-free status was sus-
tained. Sustained pain-free status was obtained by 20
subjects (27%) for attack 2, 21 subjects (31%) for
attack 3 and 23 subjects (37%) for attack 4.
Of the subjects in the ITT population, 65% of
subjects in the ITT population reported that they
would use this medication again. A total of 85% of
subjects reported that the medication was very easy
or easy to use, and 94% would treat future migraine
attacks within 30 min of onset.
Discussion
The results of this study suggest that experienced mi-
graineurs who were previously unsatisﬁed with lower
doses of sumatriptan in any form (i.e. tablets, nasal
spray or injection) and less than very satisﬁed with
their current treatment regimen are more likely to be
satisﬁed or very satisﬁed with sumatriptan RT
100 mg in an early intervention paradigm. In this
study, the mean scale scores for treatment satisfac-
tion when measured by a validated treatment satis-
faction questionnaire indicate that subjects tended to
be satisﬁed with the Efﬁcacy, Ease Of Use, Function-
ality and side effects of sumatriptan RT 100 mg
when treating migraine in an early intervention para-
digm. The treatment satisfaction results corresponded
with positive results on efﬁcacy measures and a func-
tional status measure.
The percentage of patients who were very satisﬁed
with treatment following the ﬁrst attack was lower
than the percentage at attacks 2, 3, 4, and at the fol-
low-up visit. With any new treatment or interven-
tion, experience impacts the outcome. Global
satisfaction may have been slightly lower after the
ﬁrst attack because it was the subjects’ ﬁrst experi-
ence using this intervention (EI paradigm and suma-
triptan RT 100 mg) after having reported
dissatisfaction with sumatriptan. That is, because
these subjects were previously dissatisﬁed with suma-
triptan, they may have had lower expectations at the
beginning of the study.
Additionally, the percent of patients who were sat-
isﬁed and very satisﬁed with side effects is higher for
attacks 3 and 4 than for attacks 1 and 2. While it is
possible that patients who remained in the study had
fewer or less severe side effects compared with those
who dropped out, patients may have become more
familiar with the drug and its side effects over the
course of the study. In our experience, it is not
uncommon for subjects to report fewer adverse
events (AEs) over time in long-term studies.
Treatment satisfaction, deﬁned as the subject’s
evaluation of important attributes associated with the
process and outcomes of treatment, is becoming a
more common end-point in clinical trials (27). In an
international survey of patients with a migraine diag-
nosis, only 36% reported that they were ‘very satis-
ﬁed’ with their current migraine treatment and only
27% reported that their current migraine therapy
consistently managed every migraine attack (31).
Physicians who treat patients with migraine should
be aware that their patients may not be fully satisﬁed
with their treatment regimen and should initiate dis-
cussions about treatment options. The results of this
open label study suggest that experienced migrai-
neurs might beneﬁt from modiﬁcations to their
treatment regimen including medication, dose, for-
mulation and timing of treatment administration.
Further, the consistency of treatment efﬁcacy over
repeated attacks of migraine observed in this study
may serve to increase patient conﬁdence and add
further to their satisfaction.
Other studies have demonstrated that treatment
satisfaction for migraineurs is closely linked with
clinical efﬁcacy and that patient preferences are
impacted by previous treatment experience (32–36).
This study found that the positive results on patient
satisfaction measures were consistent with the posi-
tive results on efﬁcacy measures and functional status
measures. These ﬁndings might be attributed to the
higher dose of sumatriptan, the fast disintegrating,
rapid-release formulation, the early intervention par-
adigm or a combination of all three.
Multiple studies of conventional sumatriptan
administered in an early intervention paradigm have
demonstrated that the 100 mg dose is more efﬁca-
cious than lower doses in a clinical trial setting
(15,18,19,23). These studies have also shown that
both the 50 and 100 mg doses of conventional suma-
triptan were well-tolerated, and no new or unusual
side effects were identiﬁed at the 100 mg dose
(15,18,19,23). In a pooled-analysis of six studies of
the early intervention paradigm comparing 50 mg of
conventional sumatriptan, 100 mg of conventional
sumatriptan and placebo, the results demonstrated
that both doses were well-tolerated, and that the
100 mg dose was signiﬁcantly more efﬁcacious (18).
A study of the safety and efﬁcacy of sumatriptan RT
at the 50 and 100 mg doses also found that the
100 mg dose of sumatriptan RT was superior to the
50 mg dose on multiple efﬁcacy measures and
uncovered no new or unusual side effects at either
dose (26). The results of this open-label study
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als that have demonstrated that sumatriptan RT
100 mg is effective in an early treatment paradigm
(25,26).
Improvement in functional status is an important
end-point for migraineurs because the majority of
the costs associated with migraine results from
missed time and productivity loss rather than from
direct healthcare costs (37). A productivity study of
sumatriptan 100 mg in an early intervention para-
digm found the degree of reduction in productivity
loss was inversely related to the severity of pain at
initial dosing of sumatriptan (38). Improvements in
functional status during migraine attacks may help
reduce the burden of migraine to patients and to
society. Subjects in this study reported improved
mean functional status at each time point after the
initial dose of study medication.
The results of this study should be interpreted in
the context of the limitations. Although it is desir-
able to evaluate treatment outcomes in a real-world
environment, certain biases are more likely to be
present in an open-label, uncontrolled study com-
pared with a randomised, controlled study. To
reduce the impact of selection bias, we restricted the
study population to experienced migraineurs who
reported dissatisfaction with the study drug in the
previous treatment settings and less than complete
satisfaction with their current medication regimen.
Although these subjects were less likely to represent
migraineurs with a mild condition, their experience
with the condition and treatment provided a speciﬁc
perspective on treatment satisfaction. Lost to follow
up can be a signiﬁcant source of selection bias. In
this study, the drop out rate was < 10%, which sug-
gests that the study medication and treatment regi-
men were well tolerated.
A potential source of recall bias was that subjects
were required to remember their previous experi-
ences with sumatriptan to be eligible for the study.
The impact of this was minimised by providing
potential subjects with only two options: satisﬁed or
dissatisﬁed. To reduce the recall bias associated with
the study measures, subjects were required to com-
plete the patient diary within 24 h of each attack as
opposed to waiting to report their experiences until
a study visit. This study was designed to mimic
clinical use by allowing subjects to continue with
their established prophylactic medication and to use
the rescue medication of their choice. The mean
results from all four attacks and at the follow-up
visit were similar, which suggests that the results
are valid.
A limitation in this study was that the global satis-
faction question asked at enrolment and the follow-up
global question were worded slightly differently. The
PPMQ-R includes a global satisfaction question that
asks subjects to consider their overall satisfaction with
the ‘study medication’. For screening, subjects were
asked to consider their overall satisfaction with their
current treatment regimen. The same 7-point scale
was used for measuring subject responses.
Studying an early intervention paradigm presents a
challenge because mild migraines may be self-limiting
and other types of headache may be mistaken for
mild migraines (19). However, a recent study of
migraineurs found that 92% of headaches identiﬁed as
migraines at early onset were conﬁrmed migraines at
headache peak (39). In our study, experienced
migraineurs who reported a mild pain phase preced-
ing moderate-to-severe migraines were recruited to
limit the number of non-migraine headaches mistaken
for migraines with mild pain at onset. However, by
limiting the study to patients with migraine experience
and a history of frequent and moderate or severe
attacks, the study population included patients on the
more severe end of the disease spectrum. The satis-
faction and efﬁcacy results were similar across four
attacks and at study follow up. These ﬁndings suggest
that the subjects in this study properly identiﬁed
migraine headaches in the mild pain phase.
Obtaining information about the level of satisfac-
tion with pharmaceutical products is reﬂective of the
desire to consider the perspective of the patient in
medical decision making. However, gathering infor-
mation directly from patients presents methodologi-
cal challenges. The act of asking questions about
patients’ medication may impact their responses. To
minimise the impact of examiner inﬂuence on the
results of this study, we used a validated treatment
satisfaction questionnaire.
Additional studies should be conducted to mea-
sure the relative importance of the impact of
improvement in satisfaction related to dose, treat-
ment paradigm or formulation. Although this study
does not weigh the relative contribution of early
intervention, appropriate dosing and rapid release
formulation, the results suggest that patients who
believe that sumatriptan was ineffective under differ-
ent circumstances could be rechallenged under new
treatment conditions before sumatriptan is declared
suboptimal for the patient.
In conclusion, the results of this study suggest that
for patients who are not completely satisﬁed with
their current medication regimen, physicians have an
opportunity to optimise a rapid and complete
response by encouraging patients to treat migraine
attacks using an early intervention paradigm and by
prescribing the most effective dose and a faster dis-
persing, disintegrating and absorbing formulation.
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